Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Afroditi Economidi"'
Autor:
Alexandra Karadimou, Magdalini Migou, Afroditi Economidi, Alexandros Stratigos, Christos Kittas, Meletios A. Dimopoulos, Aristotle Bamias
Publikováno v:
Case Reports in Oncology, Vol 4, Iss 2, Pp 385-391 (2011)
We report on a 63-year-old woman, previously in good health, who had undergone nephrectomy for clear cell renal cell carcinoma in 2002. Because of systemic relapse with multiple lung metastases in 2006, the patient was treated with sunitinib 50 mg da
Externí odkaz:
https://doaj.org/article/6faf1fa506424e83978c5e6652823e7f
Autor:
Triantafyllia Koletsa, Alexander J. Stratigos, Dimitris Rigopoulos, Afroditi Economidi, Aikaterini Patsatsi, Polytimi Sidiropoulou, Evangelia Papadavid, E. Georgiou, Vasiliki Nikolaou, Sabine‐Elke Kruger‐Krasagakis, Eirini Kavvalou, Gregory Chlouverakis
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADVReferences. 34(11)
Background Retinoids have long been used in the treatment of cutaneous T-cell lymphomas. However, data on acitretin use for mycosis fungoides (MF) are very limited. Objectives To evaluate treatment outcomes of acitretin in patients with MF attending
Autor:
Dimitris Rigopoulos, Leonidas Marinos, Maria A. Gerochristou, Afroditi Economidi, Alexander J. Stratigos, Vasiliki Nikolaou, Dimitra Voudouri
Publikováno v:
The Journal of dermatological treatment. 31(1)
Although anti-TNFα agents have revolutionized the treatment of many inflammatory diseases, various concerns have been reported regarding the risks of cancer development, as well as acceleration of the progression of subclinical, preexisting malignan
Autor:
Elena Komini, Dimitra Voudouri, Leonidas Marinos, Afroditi Economidi, Vasiliki Nikolaou, Polytimi Sidiropoulou, Alexander J. Stratigos, Dimitris Rigopoulos
Publikováno v:
International journal of dermatologyReferences. 59(3)
BACKGROUND Mycosis fungoides (MF) accounts for the majority of cutaneous lymphomas. Apart from the predominant Alibert-Bazin type, several clinicopathological variants of diverse prevalence and biological behavior have been described. Data on clinica
Autor:
Theodoros Iliakis, Alexandros Stratigos, L. Marinos, Afroditi Economidi, P. Panayiotidis, Dimitrios Rigopoulos, V. Nikolaou
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 33
Autor:
Polytimi Sidiropoulou, Dimitris Rigopoulos, Alexander J. Stratigos, Dimitra Voudouri, Vasiliki Nikolaou, Leonidas Marinos, Afroditi Economidi
Publikováno v:
Australasian Journal of Dermatology. 60
Autor:
Leonidas Marinos, Athanasios Sachlas, Vasiliki Nikolaou, Afroditi Economidi, Christina Antoniou, Evangelia Papadavid, Alexander J. Stratigos, Konstantina Karambidou
Publikováno v:
Photodermatology, photoimmunologyphotomedicine. 34(5)
BACKGROUND Phototherapy is one of the main treatments for mycosis fungoides (MF). In this study, we analyzed the efficacy and safety of phototherapy as a first-line treatment in patients with early-stage disease. METHODS We analyzed treatment outcome
Autor:
E. Papadavid, V. Nikolaou, Afroditi Economidi, Maria A. Gerochristou, E Economaki, E. Christofidou, E. Moustou, Alexandros Stratigos, Ch. Antoniou, A Tasidou, L. Marinos
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADV. 31(11)
Background It has been reported that patients with psoriasis are at increased risk for developing lymphoma including cutaneous T cell lymphomas (CTCL). However, the comorbidity and the histopathologic correlation of psoriasis and Mycosis Fungoides (M
Autor:
Ch. Antoniou, Aikaterini Patsatsi, Alexandros Stratigos, V. Nikolaou, Afroditi Economidi, Elisavet Georgiou, Marina P. Siakantaris, Triantafyllia Koletsa, E. Papadavid, Vassiliki Pappa, L. Marinos
Publikováno v:
The British journal of dermatology. 176(5)
Mycosis fungoides (MF) is an indolent cutaneous lymphoma with excellent prognosis at early stages and much poorer outcome during disease progression. Old age, male sex and folliculotropism have been proposed as relevant prognostic factors; however, t
Autor:
Marina P. Siakantaris, Theodoros P. Vassilakopoulos, E. Papadavid, Alexandros Stratigos, T. Papadaki, Afroditi Economidi, V. Nikolaou, Ch. Antoniou, L. Marinos
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 25:354-357
Background The combination of PUVA with variable doses of systemically administered interferon α2b (IFN-α2b) reduces the number of PUVA treatments and the dose of IFN-α2b required to produce remission in all mycosis fungoides (MF) stages. Objectiv